Pharmacological protection of vascular endothelium in acute COVID-19.
J Physiol Pharmacol
; 73(2)2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-2002832
ABSTRACT
Since the beginning of the COVID-19 pandemic, there has been an urgent need to find effective treatment. It is widely known that virus attacks and damages mostly the lungs, but also infect vascular endothelial cells. Therefore, the protection of the endothelium is a promising target in the therapy of COVID-19 and its complications. In this review article, we focused on several groups of drugs with potential to protect the endothelium. The most promising ones are angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, drugs targeting angiotensin-converting enzyme 2, heparins, sulodexide, acetylsalicylic acid, statins, tocilizumab, baricitinib, and defibrotide. Although the short period of trials and the lack of data necessitate further research, endothelial protection remains a promising target for COVID-19 therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal subject:
Pharmacology
/
Physiology
Year:
2022
Document Type:
Article
Affiliation country:
Jpp.2022.2.01
Similar
MEDLINE
...
LILACS
LIS